XBiotech Inc. — Q2 2015 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing naturally occurring “True Human” monoclonal antibodies, with Xilonix as its lead candidate. This unaudited filing covers the three and six months ended June 30, 2015; comparisons are with the corresponding 2014 periods unless otherwise noted. The company has not generated revenue.
Financial performance and position
- Revenue: None in either the second quarter or first half of 2015 or 2014.
- Q2 2015: Operating expenses were $6.421 million, up 64% from $3.905 million. Net loss was $6.744 million, versus $3.906 million; basic and diluted loss per share was $0.22, versus $0.16.
- First half 2015: Operating expenses were $14.626 million, up 74% from $8.410 million. Net loss was $14.858 million, versus $8.410 million; loss per share was $0.50, versus $0.35.
- Research and development: $4.382 million in Q2, up 35%; $11.167 million in the first half, up 100%. The first-half increase primarily reflected clinical-trial activity, laboratory and manufacturing supplies, and higher personnel costs.
- General and administrative: $2.039 million in Q2, up 209%; $3.459 million in the first half, up 23%. Quarterly increases included stock-based compensation, executive bonus, and professional fees.
- Cash flow: First-half operating cash use was $15.394 million, compared with $5.020 million in 2014. Investing cash use was $2.210 million, versus $0.317 million, including construction spending. Financing provided $77.438 million, including IPO proceeds.
- Liquidity and capitalization: Cash and cash equivalents were $117.382 million at June 30, 2015, versus $57.329 million at December 31, 2014. Total current liabilities were $2.865 million; total liabilities were $2.872 million. No debt is reported on the balance sheet. Accumulated deficit was $108.026 million.
- Margins: Not meaningful because the company had no revenue. The filing reports no product gross margin.
Material changes and notable items
- The April 2015 IPO sold 4.0 million shares at $19 per share and generated approximately $70.6 million in net proceeds. Cash also increased through warrant and option exercises. Shares outstanding were 32.041 million at June 30 and 32.053 million as of August 14, 2015.
- Construction in progress for the Austin manufacturing facility rose to $2.681 million from $0.886 million at year-end. The company reported facility construction was on schedule, with completion anticipated in March 2016 and product validation in July 2016.
- Foreign exchange loss was $0.323 million in Q2 and $0.232 million for the first half; foreign-currency translation adjustments were positive $0.317 million and $0.219 million, respectively.
- Stock-based compensation was $2.469 million for the first half. Approximately $6.2 million of unrecognized option compensation cost remained, expected to be amortized over 2.09 years.
Outlook, risks and contingencies
- Management expects substantial and increasing operating losses as it advances candidates and expands clinical programs; profitability depends on regulatory approval and successful commercialization, and may never be achieved.
- Management expected enrollment in the European Xilonix study to finish in Q3 2015 and said an EMA marketing application could be submitted by year-end, depending on study results. Potential 2017 revenue was conditional on approval and successful commercialization. Planned study expansion to additional regions was expected by year-end 2015.
- A Phase 1/2 study for a True Human antibody targeting serious Staphylococcus aureus infections was launched in May; the first patient was treated July 6, 2015. Expansion to Europe, South Korea and Taiwan was planned by year-end. The Pyoderma Gangrenosum regulatory program was on hold indefinitely.
- The company announced it had isolated and cloned an anti-Ebola product candidate using its discovery platform; the filing does not provide clinical efficacy or development timing.
- The company had no material legal proceedings, reported no material changes to previously disclosed risk factors, and stated disclosure controls were effective. It had no reported off-balance-sheet arrangements. Future minimum operating lease payments totaled $1.676 million.
- Subsequent to quarter-end, investors exercised options for 12,000 shares, generating $30,000. The company reported no material market-risk exposure and no hedging activity.
Key facts for investors to verify
- Clinical-trial enrollment, results, regulatory timing and the assumptions underlying the potential Xilonix filing and revenue timeline.
- Cash burn relative to the $117.4 million cash balance, and whether planned clinical and manufacturing spending changes the company’s funding needs.
- Progress, cost and timing of manufacturing-facility construction and validation.
- Details and development prospects for the Staphylococcus aureus and anti-Ebola candidates, including any updates beyond the filing.
- Share dilution from outstanding options and other equity awards, including the reported $6.2 million of unrecognized stock-compensation expense.